902 related articles for article (PubMed ID: 31849996)
1. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F; Meier K; Ghoreschi K
Front Immunol; 2019; 10():2847. PubMed ID: 31849996
[TBL] [Abstract][Full Text] [Related]
2. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
4. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
7. [Dermatology. New uses for JAK inhibitors in dermatology: a panacea, but at what price?].
Russo G; Laffitte E; Cortes B
Rev Med Suisse; 2024 Jan; 20(859):241-246. PubMed ID: 38299954
[TBL] [Abstract][Full Text] [Related]
8. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
9. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
10. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
12. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
13. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors in dermatology: Part II. A comprehensive review.
Chapman S; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):414-422. PubMed ID: 34228996
[TBL] [Abstract][Full Text] [Related]
15. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
Dogra S; Sharma A; Mehta H; Sarkar R
Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
[TBL] [Abstract][Full Text] [Related]
17. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
18. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
19. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
20. JAK/STAT pathway modulation: Does it work in dermatology?
Gündüz Ö
Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
